Recent findings indicate that systemic inflammation and neuroprotection strategies improve outcomes in NPSLE.
Purpose of review Here, we provide a broad overview of the current treatment landscape of neuropsychiatric systemic lupus erythematosus (NPSLE) focusing on diffuse central nervous system manifestations and potential new treatments based on studies of murine models and neuroimaging studies of patients. Recent findings The therapeutic landscape focuses on three approaches: modulation of B cell activity and circulating autoantibodies (CAR-T cell and BTK inhibitor therapies), reduction of systemic inflammation (JAK, TYK2, and anti-IFN inhibitors), and direct neuroprotection (ACE inhibitors and ARBs). Summary These findings broaden the therapeutic landscape for NPSLE beyond general immunosuppression. Future research must prioritize clinical trials inclusive of NPSLE patients to validate these promising strategies.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: